




3rd FRENCH LEBANESE ONCOLOGY MEETING FLOM

October 5 - 6, 2018
Le Bristol Hotel
Beirut - Lebanon



in collaboration with





3rd FRENCH LEBANESE ONCOLOGY MEETING - FLOM

October 5 - 6, 2018 | Le Bristol Hotel Beirut - Lebanon

Friday October 05, 2018

8:00 Registration

09:00 - 09:10 Welcome

Session 1: Hematology

09:10 - 09:30	Hematology Concepts in The Treatment of Solid Tumors	Dr. Ali N. Chamseddine Dr. Jean-Henri Bourhis
09:30 - 09:50	Diffuse Large B-Cell Lymphoma: From Molecular Level to Therapeutic Effects	Pr. Fabrice Jardin

09:50 - 10:20	Treatment Evolution in First Line Follicular Lymphoma and Chronic Lymphocytic Leukemia <i>Symposium Sponsored by Roche</i>	Pr. Fabrice Jardin
---------------	---	--------------------

10:20 - 10:50 Coffee Break

Session 2: Soft Tissue Sarcoma

10:50 - 11:20	GIST: A Proof of Concept for Molecular-Targeted Treatments	Pr. Axel Le Cesne
11:20 - 11:50	Oncological Strategies to Avoid Amputation Limb Sarcoma	Dr. Charles Honore

11:50 - 12:20	New Advances in the Treatment of Advance Soft Tissue Sarcoma <i>Symposium Sponsored by Eli Lilly</i>	Dr. Olivier Mir
---------------	---	-----------------

Session 3: Breast & Gynecology

12:20 - 12:50	Systemic Treatments in Advanced Ovarian Cancer (Anti-VEGF, PARP inh...)	Pr. Georges Chahine
12:50 - 13:20	Systemic Treatment Options to Postpone Chemotherapy in ER-Positive mBC	Dr. Olivier Mir



3rd FRENCH LEBANESE ONCOLOGY MEETING - FLOM

October 5 - 6, 2018 | Le Bristol Hotel Beirut - Lebanon

Friday October 05, 2018

13:20 - 14:05	RCC (Second Line) <i>Symposium Sponsored by Biologix</i>	Pr. Shouki Bazarbashi
14:05 - 15:05	Lunch Break	
15:05 - 15:50	Revealing the Evidence: What are the Differences Among CDK4/6 Inhibitors in MBC Management? <i>Symposium Sponsored by Pfizer</i>	Dr. Olivier Mir
15:50 - 16:35	Moving Forward: New Advances in the Management of HR+ve HER2-ve ABC Patients <i>Symposium Sponsored by Novartis</i>	Dr. Ali Shamseddine
16:35 - 16:50	Breast Cancer <i>Lecture Sponsored by Eli Lilly</i>	Pr. Fadi Farhat
16:50 - 17:20	Coffee Break	
Session 4: Gastro-Intestinal (Part 1)		
17:20 - 17:40	Recent Advances in The Locally Advanced or Metastatic Pancreatic or Biliary Tract Carcinoma	Pr. Romain Coriat
17:40 - 17:55	Prevention of GI Cancers: Aspirin, Proton Pump Inhibitors and Other Approaches	Pr. Romain Coriat



3rd FRENCH LEBANESE ONCOLOGY MEETING - FLOM

October 5 - 6, 2018 | Le Bristol Hotel Beirut - Lebanon

Saturday October 6, 2018

8:00	Registration	
Session 5: Pharmacology		
09:00 - 09:20	Systemic Cancer Treatments in Patients with Renal Failure	Dr. Olivier Mir
09:20 - 09:40	Systemic Cancer Treatments in Patients with Liver Failure	Dr. Ali N. Chamseddine
Session 6: Immuno-Oncology		
09:40 - 10:00	"Doctor, I Want Immunotherapy". Simple Basis for Rationale Answers in NSCLC and SCLC Patients	Dr. Francesca Lucibello
10:00 - 10:30	Coffee Break	
10:30 - 11:15	Role of Pembrolizumab in Non-Small Cell Lung Cancer: First Line and Second Line Treatment <i>Symposium Sponsored by MSD</i>	Dr. Nizar Bitar
11:15 - 11:45	The Microenvironment of Lung Cancer and its Therapeutic Implications	Pr. Salem Chouaib
11:45 - 12:30	Renal Cell Carcinoma: What's New in the Front Line Treatment Paradigm? <i>Symposium Sponsored by BMS</i>	TBA
Session 7: Prostate Cancer		
12:30 - 13:00	Metastatic Prostate Cancer: The Whole 2018 Paradigm	Dr. Joseph Kattan
13:00 - 14:00	Lunch Break	



3rd FRENCH LEBANESE ONCOLOGY MEETING - FLOM

October 5 - 6, 2018 | Le Bristol Hotel Beirut - Lebanon

Saturday October 6, 2018

14:00 - 14:45 First Line Treatment of mRCC:
What do we Know so Far?
Symposium Sponsored by Pfizer Dr. Ali N. Chamseddine

14:45 - 15:15 Tumor Mutational Burden (TMB):
An Emerging Predictive I-O Biomarker
Symposium Sponsored by BMS TBA

Session 8: Gastro-Intestinal (Part 2)

15:15 - 15:35 How Methodology Can Improve our Understanding
of Clinical Trials Data? The Example of Irinotecan
and The Generalized Pairwise Comparison Method
in Metastatic Gastric Cancer Dr. Ali N. Chamseddine

15:35 - 15:55 How do I Manage Colorectal Cancer Liver
Metastases? Dr. Leonor Benhaim

15:55 - 16:10 First-Line Treatment in Metastatic Gastric
Cancer: Important or Crucial? Pr. David Malka

16:10 - 16:50 Coffee Break

16:50 - 17:05 The Current Surgical Landscape in Rectal Cancer:
Highlights and Advances Dr. Leonor Benhaim

17:05 - 17:20 Management of HIPEC in Primary and Secondary
Peritoneal Cancer:
Where Do We Stand After ASCO 2018? Dr. Charles Honore

17:20 - 17:35 Advanced Neuroendocrine Gastroenteropancreatic
Carcinoma: Where Do We Stand in 2018? Pr. David Malka